|
Mutation Information
|
Mutation Site
|
E157Q |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Combined Mutation
|
in.R263K+in.E157Q+in.T66I |
|
Genotype/Subtype
|
B |
|
Viral Reference
|
AF324493.2;
AF096341.1 |
|
Relevant Drug
|
elvitegravir (EVG);raltegravir (RAL);dolutegravir (DTG);cabotegravir (CAB);bictegravir (BIC) |
|
Country
|
Canada |
Literature Information
|
PubMed PMID
|
30119633
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2018 |
|
Journal
|
Retrovirology |
|
Title
|
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. |
|
Author
|
Oliveira M,Ibanescu RI,Anstett K,Mésplède T,Routy JP,Robbins MA,Brenner BG,Montreal Primary HIV (PHI) Cohort Study Group. |
|
Evidence
|
Here, in vitro drug selections compared the development of resistance to DTG, BIC, CAB, EVG and RAL using clinical isolates from treatment-naive primary HIV infection (PHI) cohort participants (n = 12), and pNL4.3 recombinant strains encoding patient-derived Integrase with (n = 5) and without (n = 5) the E157Q substitution.
|
|
|
HIV Mutation Detail Information